Bd reports third quarter fiscal 2025 financial results

Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted fxn and 3.0% organic gaap and adjusted diluted eps grew to $2.00 and $3.68, respectively gaap and adjusted gross margin up 160 basis points and 50 basis points, respectively, driven by bd excellence gaap and adjusted operating income up 46.6% and 11.3%, respectively company raises full-year adjusted diluted eps guidance to $14.30 to $14.45, reflecting an $0.18 increase to 9.4% growth at the midpoint, while reaffirming organic revenue growth guidance1 expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025 franklin lakes, n.j. , aug. 7, 2025 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its fiscal 2025 third quarter, which ended june 30, 2025.
BDX Ratings Summary
BDX Quant Ranking